Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA(2023)
Key words
AML, ivosidenib, acute myeloid leukemia, AGILE, mutant IDH1, azacitidine, phase III
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined